期刊文献+

抗人类免疫缺陷病毒先导物DAAN-5508的大鼠药动学研究

Pharmacokinetics Study of the Anti-HIV Lead Compound DAAN-5508 in Rats
原文传递
导出
摘要 目的建立检测大鼠血浆中抗人类免疫缺陷病毒(human immunodeficiency virus,HIV)候选化合物DAAN-5508的LC—MS/MS方法,并将其应用于大鼠体内药动学研究。方法血浆样品用甲醇沉淀蛋白处理;色谱分离用含0.1%甲酸的甲醇和水为流动相梯度洗脱,流速为0.3mL·min^-1。定量分析在Triple Quad LC—MS/MS上采用电喷雾离子化电离源(ESI)、正离子多重反应离子监测(MRM)的方式进行。将建立的方法应用于大鼠静注和口服DAAN-5508的药动学和生物利用度研究。结果DAAN-5508在0.2~2500ng·mL^-1内呈良好的线性关系(r^2=0.9998),最低定量限为0.2ng·mL^-1。方法的回收率〉80%,日内和日间精密度和准确度符合生物样品的检测要求。大鼠静注(5mg·kg^-1)和口服(15mg·kg^-1)DAAN-5508后,静注和口服的消除半衰期分别为2.6和4.6h。大鼠口服后DAAN-5508的吸收较快,血浆浓度在1h左右达到(188.0±62.33)ng·mL^-1的峰值,口服生物利用度为12%。结论本实验建立了特异、灵敏、简便快捷的定量检测血浆DAAN-5508的LC—MS/MS方法,成功应用于DAAN-5508的大鼠药动学和生物利用度研究。 OBJECTIVE To develop and validate a LC-MS/MS method for quantitative analysis of the new anti-14IV candidate DAAN-5508 in rat plasma, and to study its pharmacokinetics and bioavailability in rats. METHODS The plasma samples were treated with methanol for precipitating proteins. The chromatographic separation was performed with a gradient elution using 0. 1% fomuc acid solution and methanol containing 0. 1% formic acid. The flow rate was 0. 3 mL · min^-1. The MS detection was conducted using an LC-MS/MS in positive ion electrospray and multiple reactions monitoring (MRM) mode. RESULTS Good linearity was obtained over the concentration range of 0. 2 - 2 500 ng · mL^-1 for DAAN-5508 ( r^2 = 0. 999 8), with the lower limit of quantification at 0.2 ng · mL^-1. The recovery of DAAN-5508 was greater than 80%. The precision and the accuracy met the requirements for bioanalysis. The method was applied for pharmacokineties study of DAAN-5508 in rats. After a single iv(5 mg· kg^-1 )Or oral dose ( 15 mg· kg^-1 )of DAAN-5508 to rats, the plasma coneentration of DAAN-5508 showed a biphasic decline. The elimination half-lives were 2. 6 and 4. 6 h for intravenous and oral administration, respectively. The absorption of DAAN-5508 was rapid after oral administration. The peak level ( 188.0 ± 62. 33 ) ng · mL^-1 was reached at 1 h. The oral bioavailability was 12%. CONCLUSION The developed the LC-MS/MS method is selective, sensitive, rapid and simple. It is suitable for the in vivo pharmacokinetics study of DAAN-5508 in rats.
出处 《中国药学杂志》 CAS CSCD 北大核心 2014年第8期674-678,共5页 Chinese Pharmaceutical Journal
基金 国家自然科学基金重点项目(30930106) 国家"重大新药创制"科技重大专项(2008ZXJ09006-001)
关键词 非核苷类RT酶抑制剂 二芳烃取代苯胺类化合物 液相色谱-串联质谱法 药动学 生物利用度 non-nucleoside reverse transcriptase inhibitors diarylaniline liquid chromatography/tandem mass spectrometry pharmacokineties bioavailability
  • 相关文献

参考文献1

二级参考文献6

  • 1Domaoal RA, Demeter LM. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors [ J ]. lnt J Biochem Cell Biol, 2004, 36(9) :1735-1751.
  • 2Pauwels R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections[ J ]. Curt Opin Pharmacol, 2004, 4 ( 5 ) :437-446.
  • 3Haslinger BA, Arendt: G. TMC-125 Tibotec[ J]. Curr Opin Invest Drugs, 2004, 5(2) :208-213.
  • 4Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-genera- tion nonnucleoside reverse transcriptase inhibitor ( NNRTI ), ac- tive against wild-type and NNRTI-resistant HIV-1 [ J]. Antimicrob Agents Chemother, 2010, 54(2) :718-727.
  • 5Tian XT, Qin B J, Wu ZY, et al. Design, synthesis, and evalua- tion of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors [ J]. J Med Chem, 2010, 53 : 8287-8297.
  • 6Tian XT, Qin B J, Lu H, et al. Discovery of diarylpyridine deriva- tives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors [ J ]. Bioorg Med Chem Lett, 2009, 19 ( 18 ) :5482-5485.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部